Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept Phase III in Generalized Myasthenia Gravis
NCT05737160Phase 3Completed
- Sponsor
- RemeGen
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in myasthenia gravis (MG), sponsored by RemeGen. Started Mar 2023; status: completed.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05737160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737160.